Recombinant Human IGFBP5 protein (ab49835)
Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Endotoxin level: < 0.100 Eu/µg
- Suitable for: WB, Inhibition Assay, Functional Studies, SDS-PAGE
Description
-
Product name
Recombinant Human IGFBP5 protein -
Purity
> 95 % SDS-PAGE.
Greater than 98% by SDS-PAGE gel and HPLC analyses. -
Endotoxin level
< 0.100 Eu/µg -
Expression system
Escherichia coli -
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS
-
Specifications
Our Abpromise guarantee covers the use of ab49835 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Western blot
Inhibition Assay
Functional Studies
SDS-PAGE
-
Form
Lyophilized -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Constituent: 0.294% Sodium citrate
Endotoxin level is less than 0.1 ng per µg (1EU/µg). -
ReconstitutionReconstitute in water to a concentration of 0.1-1.0 mg/ml.
General Info
-
Alternative names
- IBP 5
- IBP-5
- IBP5
see all -
Function
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. -
Tissue specificity
Osteosarcoma, and at lower levels in liver, kidney and brain. -
Sequence similarities
Contains 1 IGFBP N-terminal domain.
Contains 1 thyroglobulin type-1 domain. -
Cellular localization
Secreted. - Information by UniProt
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (2)
ab49835 has been referenced in 2 publications.
- Slocum E et al. Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Res 21:56 (2019). PubMed: 31046834
- Abrass CK & Hansen KM Insulin-like growth factor-binding protein-5-induced laminin gamma1 transcription requires filamin A. J Biol Chem 285:12925-34 (2010). PubMed: 20167606